All In Biotech

Drug Trial Radar · NCT07836270

A Study of Ecnoglutide Injection in Overweight or Obese Chinese Adolescents

A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Safety and Efficacy of Ecnoglutide Injection in Overweight or Obese Chinese Adolescents (SLIMMER-YOUNG)

Last checked: Nov 19, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 192 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

192

Planned (sponsor's estimate)

Start

Oct 31, 2026

Primary completion

Jun 8, 2028

Study completion Sep 30, 2028

Sponsor

Sponsor type
Industry
First posted
Sep 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of the study is to evaluate the safety and efficacy of Ecnoglutide injection in overweight or obese Chinese adolescents

Conditions

  • Adolescents With Obesity
  • Adolescents With Overweight & Weight-related Comorbidities

Interventions

  • Ecnoglutide InjectionDrug

    Subcutaneous injection

  • placebo with matching volumeDrug

    Subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change in Body Mass Index (BMI)Time frame: Baseline, week 40

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Children's Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.